Methods: Patients with prostate cancer diagnosed from January 1, 1975 to December 31, 2019 in the Surveillance, Epidemiology, and End Results Program (SEER) database were extracted by SEER stat software for epidemiological trend analysis. General clinical information and follow-u...
Prostate cancer is a common malignant tumor in elderly men in western countries. In the past decade, the incidence and mortality of prostate cancer in China have shown a rapid upward trend. With the changes of social economy, life style and the progress of diagnosis and treatment, the epidemio...
Epidemiology Prostate cancer is diagnosed in very few people aged younger than 50 years (<0·1% of all patients). The mean age of patients with this disorder is 72–74 years, and about 85% of patients are diagnosed after age 65 years (figure 1). At age 85 years the cumulative risk of...
When it came to patients with stage I or II prostate cancer, meanwhile, clinic outcomes matched those reflected in national averages described in NCI Surveillance Epidemiology and End Results (SEER) data, with 10-year survival data approaching 100%.By administering a six-item questionnaire to pati...
Prognostic evaluation of polygenic risk score underlying pan-cancer analysis: evidence from two large-scale cohorts. EBioMedicine. 2023;89: 104454. Article CAS PubMed PubMed Central Google Scholar Schaid DJ, Sinnwell JP, Batzler A, McDonnell SK. Polygenic risk for prostate cancer: decreasing ...
The 7 major metastatic castration-resistant prostate cancer markets are expected to exhibit a CAGR of 5.44% during 2023-2034. This report provides an exhaustive analysis of the metastatic castration-resistant prostate cance...
National Cancer Institute Surveillance, Epidemiology, and End Results Program website. seer.cancer.gov/statfacts/html/prost.html. Accessed July 26, 2018. Harryman WL, Hinton JP, Rubenstein CP, et al. The cohesive metastasis phenotype in human prostate cancer. Biochim Biophys Acta. 2016;1866(2)...
https://doi.org/10.1515/med-2023-0875Cite this Share this Abstract Prostate cancer (PCa) represents a substantial global health concern and a prominent contributor to male cancer-related mortality. The aim of this study is to explore the role of B-type endothelin receptor (EDNRB) in PCa and...
Statin use and outcomes of oncological treatment for castration-resistant prostate cancer Article Open access 01 November 2023 Introduction Statins are competitive antagonists of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, whose activity is rate-limiting for the biosynthesis of cholesterol...
BMC Urology(2023) Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer Masashi Oshima Ken-ichi Takayama Satoshi Inoue Scientific Reports(2023) Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US,...